CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
Efficacy and safety of ofatumumab and siponimod compared to fingolimod in pediatric patients with multiple sclerosis...
Phase 3
Washington, District of Columbia, United States and 56 other locations
will evaluate the pharmacokinetics, safety and tolerability, and immunogenicity of ocrelizumab administered subcutaneously to participants with multiple...
Phase 1
Baltimore, Maryland, United States and 19 other locations
sclerosis (MS) and have recently been advised to start the medication ublituximab (Briumvi) or are currently on another medication ...
Baltimore, Maryland, United States
Many patients with multiple sclerosis (MS) experience "relapses" of disease activity during which they have increased numb...
Baltimore, Maryland, United States
In this study, researchers will learn more about a study drug called BIIB091 in participants with MS who may be experiencing relapses. It is...
Phase 2
Lutherville, Maryland, United States and 76 other locations
of nasal foralumab in patients with non-active secondary progressive multiple sclerosis (SPMS).The primary objectives that this stu...
Phase 2
Baltimore, Maryland, United States and 4 other locations
Fatigue is a prevalent and disabling symptom in Multiple Sclerosis (MS), affecting up to 90% of patients. Current treatmen...
Phase 2
Baltimore, Maryland, United States
This study will evaluate if relapsing-remitting MS patients that have not had a relapse in the past year would benefit from a switch to ofat...
Phase 4
Lutherville, Maryland, United States and 40 other locations
This double-blind, double-dummy study will evaluate the safety and efficacy of ocrelizumab compared with fingolimod in children and adolescents with...
Phase 3
Baltimore, Maryland, United States and 106 other locations
This study aims to examine the efficacy and safety of obexelimab in participants with relapsing multiple sclerosis...
Phase 2
Vienna, Virginia, United States and 48 other locations
Clinical trials
Research sites
Resources
Legal